GHK-Cu and skin claims: what the evidence supports

A short video circulating on TikTok presents a peptide injection as a single-session solution for body sculpting, increased metabolic rate, skin tightening, and cellulite reduction. The caption, originally in Arabic, uses phrases like “body contouring,” “increased burn rate,” and “skin tightening and cellulite” in the context of one session. While the creator does not name the peptide explicitly in the text, the visual and hashtag context point to a copper peptide—most likely GHK-Cu, given its well-known association with skin remodeling and its growing popularity in aesthetic clinics.

What the clip is claiming

The clip implies that a single injection of a peptide can simultaneously reshape body contours, elevate basal metabolic rate, tighten skin, and reduce cellulite. It also frames the treatment as an alternative to bariatric surgery, a claim that carries significant medical weight. The tone is promotional, and the 15-second format leaves no room for nuance about dosing, number of sessions, or evidence strength.

What the research neighborhood actually covers

GHK-Cu is one of the most studied copper peptides in dermatology and wound healing. Its role in collagen synthesis, fibroblast proliferation, and anti-inflammatory signaling is supported by decades of in vitro and animal studies, as well as some human trials for skin rejuvenation. Topical GHK-Cu has been shown to improve skin elasticity, reduce fine lines, and support post-procedure healing. However, the peptide’s effects on systemic metabolism, fat oxidation, or body composition are not established in the peer-reviewed literature. No robust clinical trial has demonstrated that GHK-Cu injections—at any dose—can increase resting metabolic rate or produce measurable fat loss in humans.

Limits, missing context, and what a 15-second clip cannot show

The clip omits several critical details. First, it does not specify the peptide identity, concentration, or injection protocol. Second, it conflates acute effects with long-term remodeling: skin tightening and cellulite reduction, if they occur, would require repeated sessions over weeks or months, not a single injection. Third, the claim about “increased burn rate” is not supported by any mechanistic data for GHK-Cu. While some peptides in the research catalog (e.g., AOD9604, MOTS-c) are being investigated for metabolic effects, GHK-Cu is not among them. Finally, the video’s framing as a “sleeve surgery alternative” is medically irresponsible, as no peptide has been approved for weight loss or as a bariatric substitute.

How this maps to named research compounds

If the clip is indeed about GHK-Cu, the only catalog compound that aligns with the skin-related portion of the claim is GHK-Cu itself. Its research use is primarily in dermatology and regenerative medicine. For the metabolic and fat-loss claims, the catalog offers compounds like AOD9604 (Fragment 176-191), MOTS-c, and SLU-PP-332, which are studied for their potential effects on lipid metabolism or energy expenditure—but none are approved for weight loss, and none have been shown to work in a single session. The clip’s “one session” framing is not consistent with how any research peptide is used in clinical studies.

Research-use caveat

All peptides mentioned here are intended for research use only. They are not approved for human therapeutic use, and no claim of safety or efficacy for any medical condition should be inferred. Researchers should consult primary literature and follow institutional guidelines when designing studies.

Open the full video fact-check page (transcript, takeaways, embedded clip).